William Blair Downgrades Calithera Biosciences (CALA) to Market Perform, Following Clinical Business Update
Tweet Send to a Friend
William Blair analyst Matt Phipps downgraded Calithera Biosciences (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
